Language: BG BG
nav.cta
Търсене, моля изчакайте...
Филтри 1
Изчисти
Статус
Фаза
Цел
Пол
Възраст
Държава
Филтри 1
Изчисти
Статус
Фаза
Цел
Пол
Възраст
Държава
Активни: Recruiting ×
Намерени 4,436 изпитвания Стр. 156 от 222
Recruiting
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
Hypochondroplasia

This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.

Начало: 27.11.2023 Край: 31.12.2043 Възраст: до 15 г.
Argentina, Australia, Brazil +8 BioMarin Pharmaceutical NCT06212947
Recruiting Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Locally Advanced Solid Tumors Recurrent Solid Tumors Metastatic Solid Tumors

This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion.

Начало: 27.11.2023 Край: 31.12.2027 Възраст: от 18 г. Treatment
Australia, Canada, Singapore +2 Genentech, Inc. NCT06031441
Recruiting
AusCADASIL: An Australian Cohort of CADASIL
Cadasil

The aim of this project is to establish an Australian cohort of patients diagnosed with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). This study will examine the clinical features and longitudinal course of CADASIL. Outcome measures include neuropsychological profile, neuroimaging, genetics, blood biomarkers, and retinal imaging.

Начало: 25.11.2023 Край: 31.03.2027 Възраст: от 18 г.
Australia Perminder Sachdev NCT06148051
Recruiting Phase 2/3
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Lymphatic Malformations

The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as compared to placebo.

Начало: 24.11.2023 Край: 02.05.2033 Възраст: до 100 г. Treatment
Argentina, Australia, Belgium +7 Novartis Pharmaceuticals NCT05948943
Recruiting
3D Printed Custom Applicators for HDR BT (DISCO)
Gynecologic Cancer Endometrial Cancer Vaginal Cancer Vulva Cancer

Intracavitary brachytherapy for gynaecological cancer currently use cylinder-type applicators or custom wax moulds to place a radioactive source in close proximity to the treatment area and provide highly conformal dose distributions. This study is a Phase IIa non-randomised interventional pilot trial that will investigate the feasibility of successfully treating patients with 3D-printed custom applicators.

Начало: 24.11.2023 Край: 01.09.2028 Възраст: от 18 г. Treatment
Australia Royal North Shore Hospital NCT06432478
Recruiting Phase 4
Antibiotics and Vaccine Immune Responses Study
Vaccine Response Impaired

The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination. The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system?

Начало: 23.11.2023 Край: 01.10.2028 Възраст: 18–35 г. Basic science
Australia South Australian Health and Medical Research Institute NCT06148025
Recruiting Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Breast Cancer

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.

Начало: 23.11.2023 Край: 30.09.2030 Възраст: от 18 г. Treatment
Argentina, Australia, Brazil +21 AstraZeneca NCT06103864
Recruiting Phase 3
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Metastatic Castration-Sensitive Prostate Cancer

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.

Начало: 21.11.2023 Край: 30.04.2031 Възраст: 18–130 г. Treatment
Australia, Belgium, Brazil +23 AstraZeneca NCT06120491
Recruiting Phase 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Colorectal Neoplasms Carcinoma, Non-Small-Cell Lung Stomach Neoplasms Pancreatic Ductal Adenocarcinoma +2

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Participants in this study must have cancer that has come back or did not get better with treatment. Participants must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called PF-08046050. PF-08046050 is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will test the safety of PF-08046050 in participants with solid tumors that are hard to treat or have spread throughout the body. This study has 5 different study parts. Part A and Part B of the study will find out how much PF-08046050 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046050 is safe and if it works to treat certain solid tumor cancers. Part D and E of the study, together with information from Parts A and B, will find out how much PF-08046050 should be given in combination with other anti-cancer agents. Part E will use the information from Parts A, B, and D to see if PF-08046050 is safe in combination with other anti-cancer agents and if it works to treat a certain solid tumor.

Начало: 20.11.2023 Край: 12.09.2030 Възраст: от 18 г.
Canada, China, France +5 Seagen, a wholly owned subsidiary of Pfizer NCT06131840
Recruiting Phase 2
Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma
Clinical Stage I Esophageal Adenocarcinoma AJCC v8 Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Stage II Esophageal Adenocarcinoma AJCC v8 Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 +2

This phase II trial tests how well preoperative (prior to surgery) radiation therapy with fluorouracil, oxaliplatin, and leucovorin calcium (FOLFOX) works for the treatment of stage I-III esophageal or gastroesophageal junction adenocarcinoma. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Fluorouracil stops cells from making deoxyribonucleic acid (DNA) and it may kill tumor cells. Leucovorin is not a chemotherapy medication but is given in conjunction with chemotherapy. Leucovorin is used with the chemotherapy medication fluorouracil to enhance the effects of the fluorouracil, in other words, to make the drug work better. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill tumor cells. Giving preoperative hypofractionated radiation with fluorouracil and oxaliplatin may kill more tumor cells in patients with stage I-III esophageal or gastroesophageal junction adenocarcinoma.

Начало: 20.11.2023 Край: 30.05.2027 Възраст: от 18 г.
United States Mayo Clinic NCT06078709
Recruiting Phase 3
A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)
Breast Neoplasm Female Radiotherapy Cosmetic Outcome

The primary objective of this study is to determine in women with node negative BC ≤3cm in size, if PBI compared to WBI, both given once-a-day over 1 week following BCS, is non-inferior for LR and reduces adverse cosmesis. The primary outcomes are LR and patient-assessed cosmesis at 3 years post randomization.

Начало: 20.11.2023 Край: 01.11.2031 Възраст: 50–120 г. Treatment
Australia, Canada Ontario Clinical Oncology Group (OCOG) NCT05417516
Recruiting Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Obesity Overweight

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.

Начало: 17.11.2023 Край: 01.09.2026 Възраст: 18–75 г.
Argentina, United States Eli Lilly and Company NCT06143956
Recruiting Phase 2
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
Non-muscle-invasive Bladder Cancer

The purpose of this research is to determine whether bladder cancer monitoring can be improved by replacing some cystoscopy procedures with urine testing. Specifically, this study examines whether there are any differences in urinary symptoms, discomfort, number of invasive procedures, anxiety, complications, cancer recurrence or cancer progression when some cystoscopy procedures are replaced with urine testing.

Начало: 17.11.2023 Край: 30.12.2028 Възраст: от 18 г.
United States White River Junction Veterans Affairs Medical Center NCT05796375
Recruiting Phase 2
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
TNBC - Triple-Negative Breast Cancer Breast Cancer

This is an open-label prospective, single institution, Phase II study of pembrolizumab in combination with radiation therapy and CSF-1R inhibition in patients with high-risk TNBC. The primary objective is to assess the pathologic complete response (pCR) rate where pCR is defined as the absence of invasive disease in the breast and lymph nodes at the time of standard of care (SOC) treatment. Secondary objectives include evaluating the change in tumor infiltrating lymphocytes (TILs), safety and tolerability of the combination, progression-free survival, event-free survival, overall survival, and node clearance.

Начало: 17.11.2023 Край: 01.12.2026 Възраст: от 18 г.
United States Stephen Shiao NCT05491226
Recruiting Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.

Начало: 16.11.2023 Край: 29.06.2032 Възраст: 18–100 г. Treatment
Argentina, Australia, Austria +35 Amgen NCT05920356
Recruiting Phase 3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast Cancer Advanced Breast Cancer Metastatic Breast Cancer ER Positive Breast Cancer +1

This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.

Начало: 16.11.2023 Край: 30.09.2027 Възраст: от 18 г. Treatment
Argentina, Australia, Belgium +21 Olema Pharmaceuticals, Inc. NCT06016738
Recruiting
Disparities Among Liver Transplant Patients
End Stage Liver DIsease

The purpose of this study is to inform healthcare interventions to reduce the disparities in liver transplant listing and in transplantation.

Начало: 15.11.2023 Край: 01.07.2026 Възраст: 18–65 г.
United States Mayo Clinic NCT05981196
Recruiting Phase 3
CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
Cardiomyopathies Myocarditis Inflammatory Cardiomyopathy Heart Failure +1

Two-parallel groups randomized, single-blinded, multi-center phase III controlled trial in patients with chronic inflammatory cardiomyopathy to assess the efficacy of colchicine and associated prospective registry to assess the prognostic value of positive genetic testing in this population.

Начало: 14.11.2023 Край: 02.05.2028 Възраст: от 18 г.
Italy Niguarda Hospital NCT06158698
Recruiting Phase 1/2
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Non-Small Cell Lung Cancer (NSCLC) Colorectal Cancer Pancreatic Ductal Adenocarcinoma

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Начало: 14.11.2023 Край: 01.06.2029 Възраст: от 18 г.
France, Germany, Italy +4 Revolution Medicines, Inc. NCT06128551
Recruiting
Long Term Outcome of Easophageal Atresia : Transmics Profiles in Adolescence
Esophageal Atresia

Oesophageal atresia (OAEA), a malformation of the oesophagus present from birth, is characterized by the interruption of the continuity of the oesophagus, which then ends in a cul-de-sac. (Source: Fimatho) An operation is then required to restore continuity to the esophagus. Although this operation enables the vast majority of children to survive the neonatal period, health problems such as gastro-oesophageal reflux, eating difficulties, respiratory problems and growth problems persist throughout life. The aim of the project is to create a prospective cohort of adolescents aged 13/14, nested in the national AO registry. of adolescents born with esophageal atresia, including a biobank of esophageal mucosa and plasma blood samples. Once the clinical and omic data have been collected, the data will be transferred to the France Cohortes information system for analysis, in order to assess the long-term outcome of this rare disease and establish multi-omic profiles. Once the clinical data have been collected and the omics data (derived from analysis of the biobank's biological samples) have been generated, they will be analyzed by the project partners to assess the long-term outcome of OA and establish multiomic profiles. The raw data will be available on the France Cohorte platform.

Начало: 14.11.2023 Край: 14.11.2026 Възраст: 13–14 г.
France, Martinique, Reunion University Hospital, Lille NCT05995171
1 … 154 155 156 157 158 … 222